18F-氟化钠PET/CT在前列腺癌骨转移223Ra治疗疗效评估中的作用
结果显示基线SUVmax和223Ra剂量可预测ADC反应,但SUVmax与Ki的变化不能预测ADC变化,提示PET/CT变化反映223Ra对成骨细胞的作用而非杀肿瘤效应。
要点
- 基线SUVmax是ADC反应的最佳预测因子,其次为223Ra剂量。
- 治疗后SUVmax与Ki下降不能预测ADC变化,不应解读为肿瘤退缩。
- PET/CT与MRI指标在疗效评估中呈现解耦联。
核心结论
- 基线SUVmax是ADC反应的最佳预测因子,其次是223Ra剂量。
- SUVmax和Ki的变化不能预测ADC变化,提示PET/CT变化反映223Ra对成骨细胞的作用而非杀肿瘤效应。
- 治疗后[18F]NaF PET/CT上SUVmax下降不应被解读为肿瘤退缩的证据。
研究设计与样本
- 基线和第4、12、24周采集全身弥散加权MRI和[18F]NaF PET/CT图像。
- 每位参与者最多监测5个骨转移灶的ADC、SUVmax及基于左心室PET/CT SUV测量的Ki替代值。
- 采用多线性回归分析(MLR)判断ADC变化是否由SUVmax或Ki变化预测,223Ra剂量和基线SUVmax为额外自变量。
主要发现
- 研究期间ADC值升高,而SUVmax和Ki下降。
- MLR分析显示基线SUVmax和223Ra剂量可预测ADC反应(分别为P < 0.001和P < 0.01)。
- 第4、12、24周SUVmax和Ki的变化均未能预测ADC变化,显示MRI与PET/CT作为疗效标志物之间的解耦联。
- Ki变化是SUVmax变化的 highly significant 预测因子(P < 0.001),反映两者强相关。
关键数值与推荐
- 223Ra给药方案为55或88 kBq/kg,最多6个周期,间隔四周。
- 基线SUVmax预测ADC反应P < 0.001,223Ra剂量预测ADC反应P < 0.01。
- Ki变化预测SUVmax变化P < 0.001。
临床怎么用
- 治疗后[18F]NaF PET/CT上SUVmax下降不应直接解读为肿瘤退缩。
- 基线SUVmax和223Ra剂量可用于预测ADC反应,但PET/CT动态变化不宜单独作为疗效判断依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The REASURE study investigated imaging biomarkers in men receiving 223Ra treatment for prostate cancer bone metastases. We used REASURE data to compare and contrast the roles of [18F]NaF PET/CT measurements of maximum standardised uptake value (SUVmax) and bone metabolic flux (Ki) as markers of response. METHODS: Thirty-four men with prostatic bone metastases received up to six cycles of 223Ra (55 or 88 kBq/kg) at four-weekly intervals. Whole-body diffusion-weighted MRI and [18F]NaF PET/CT images were acquired at baseline and 4, 12, and 24 weeks later. Values of the apparent diffusion coefficient (ADC, a measure of tumour response), SUVmax, and a novel surrogate measurement of Ki using a PET/CT SUV measurement in the left ventricle were monitored in up to 5 bone metastases in each participant. Multilinear regression analysis (MLR) was performed to determine if changes in ADC were predicted by changes in SUVmax or Ki. Radium dose and baseline SUVmax were additional independent variables. RESULTS: ADC values increased throughout the study, while SUVmax and Ki decreased. MLR analysis showed that baseline SUVmax and 223Ra dose predicted ADC response (P < 0.001 and P < 0.01, respectively). Changes in SUVmax and Ki at 4, 12, and 24 weeks failed to predict the changes in ADC, showing decoupling between MRI and PET/CT measurements as markers of response. Changes in Ki were a highly significant predictor of changes in SUVmax (P < 0.001), reflecting the strong correlation between these two measurements. CONCLUSIONS: Baseline SUVmax was the best predictor of ADC response, followed by 223Ra dose. Changes in SUVmax and Ki failed to predict changes in ADC, suggesting that the changes in the PET/CT variables reflected the effect of 223Ra uptake on osteoblasts rather than a tumoricidal effect. A decrease in SUVmax seen on post-therapy [18F]NaF PET/CT scans should not be interpreted as evidence of tumour regression. TRIAL REGISTRATION: ISRCTN ISRCTN17805587. Registered 21/01/15.
引用
- Blake GM, Donners R, Moore AEB, et al. Does 18F-sodium fluoride PET/CT have a role in the assessment of response to 223Ra therapy in men with prostatic bone metastases? Eur J Nucl Med Mol Imaging. 2026. PMID: 42321542. doi:10.1007/s00259-026-08009-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。